ANIX
Anixa Biosciences Inc (ANIX
NASDAQ · Healthcare · Biotechnology · US
$2.61
−2.25%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.66
From 52W high−50.00%
Volume91243.00
Market cap$90.73M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.66
From 52W high
−50.00%
Volume
91243.00
Market cap
$90.73M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.2x
P/E (TTM)
—
RSI (14)
40.6
MomentumView details →
1D Return
−2.25%
YTD Return
−14.10%
SummaryUpdated Jul 1, 2026
Anixa Biosciences, Inc. (NASDAQ:ANIX) is a biotechnology company founded in 1982 and originally incorporated as ITUS Corporation before changing its name in October 2018. Based in San Jose, California, the company has transitioned from its original business focus to become a clinical-stage biotechnology firm developing innovative therapies and vaccines for oncology and infectious diseases. The company went public in 1983 and has since evolved into a research-focused organization targeting critical unmet medical needs through advanced immunotherapy and vaccine technologies.
Similar companies
Latest newsMore news →
Anixa Biosciences is developing a breast cancer vaccine, currently about one-third of the way through human testing, designed to prevent recurrence and potentially the disease itself.20d agoAnixa Biosciences received an Australian patent for its breast cancer vaccine.29d agoAnixa Biosciences was granted a Korean patent for its breast cancer vaccine by the Korean Ministry of Intellectual Property, extending protection through 2040.113d ago